Pharmaceutical Products Companies By Eps

Earnings Per Share
Earnings Per ShareEfficiencyMarket RiskExp Return
1NEUP Neuphoria Therapeutics
10.93
 0.08 
 6.32 
 0.52 
2XOMAP XOMA Corp
1.0
 0.04 
 0.54 
 0.02 
3XOMAO XOMA Corporation
1.0
 0.07 
 0.28 
 0.02 
4DTIL Precision BioSciences
0.4
 0.08 
 6.29 
 0.48 
5SABSW SAB Biotherapeutics
0.29
 0.01 
 21.85 
 0.17 
6VCEL Vericel Corp Ord
0.2
(0.11)
 2.57 
(0.28)
7DVAX Dynavax Technologies
0.2
 0.08 
 1.48 
 0.11 
8TLX Telix Pharmaceuticals Limited
0.09
 0.07 
 3.32 
 0.23 
9MNKD MannKind Corp
0.08
(0.23)
 1.93 
(0.45)
10OKUR OnKure Therapeutics,
0.08
(0.18)
 4.19 
(0.76)
11ZYBT Zhengye Biotechnology Holding
0.06
 0.13 
 6.48 
 0.85 
12037411AR6 APACHE P 6
0.0
(0.04)
 1.95 
(0.07)
13MDCX Medicus Pharma Ltd
0.0
 0.07 
 8.70 
 0.61 
14037411AY1 APACHE P 525
0.0
 0.01 
 2.16 
 0.01 
1563938CAJ7 Navient 675 percent
0.0
(0.04)
 0.48 
(0.02)
1663938CAL2 US63938CAL28
0.0
(0.04)
 1.83 
(0.08)
17CDIOW Cardio Diagnostics Holdings
0.0
(0.01)
 16.93 
(0.13)
1863938CAK4 Navient 5 percent
0.0
 0.02 
 0.80 
 0.01 
1963938CAM0 US63938CAM01
0.0
(0.10)
 1.60 
(0.17)
20037411AW5 APACHE P 51
0.0
(0.04)
 2.31 
(0.10)
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure. Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.